Inlight Wealth Management LLC Acquires New Holdings in AstraZeneca PLC (NASDAQ:AZN)

Inlight Wealth Management LLC acquired a new stake in AstraZeneca PLC (NASDAQ:AZN) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 1,000 shares of the company’s stock, valued at approximately $74,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Dynamic Advisor Solutions LLC grew its position in AstraZeneca by 58.4% in the 1st quarter. Dynamic Advisor Solutions LLC now owns 13,055 shares of the company’s stock valued at $960,000 after acquiring an additional 4,811 shares in the last quarter. Geode Capital Management LLC grew its position in AstraZeneca by 1.1% in the 4th quarter. Geode Capital Management LLC now owns 498,831 shares of the company’s stock valued at $32,683,000 after acquiring an additional 5,384 shares in the last quarter. Dorsey & Whitney Trust CO LLC grew its position in AstraZeneca by 0.5% in the 4th quarter. Dorsey & Whitney Trust CO LLC now owns 35,300 shares of the company’s stock valued at $2,313,000 after acquiring an additional 189 shares in the last quarter. Brandywine Global Investment Management LLC acquired a new position in AstraZeneca in the 4th quarter valued at about $28,071,000. Finally, Farther Finance Advisors LLC grew its position in AstraZeneca by 13.1% in the 1st quarter. Farther Finance Advisors LLC now owns 6,083 shares of the company’s stock valued at $442,000 after acquiring an additional 706 shares in the last quarter. 20.35% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, BNP Paribas began coverage on AstraZeneca in a research report on Tuesday, April 15th. They issued an “outperform” rating and a $75.00 target price for the company. One analyst has rated the stock with a hold rating, five have issued a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $85.00.

AstraZeneca Stock Performance

Shares of AstraZeneca stock opened at $69.95 on Friday. AstraZeneca PLC has a one year low of $61.24 and a one year high of $87.68. The company has a market cap of $216.94 billion, a PE ratio of 28.09, a P/E/G ratio of 1.28 and a beta of 0.38. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.70 and a current ratio of 0.90. The business has a 50-day simple moving average of $70.34 and a 200-day simple moving average of $70.42.

AstraZeneca (NASDAQ:AZN) last announced its quarterly earnings data on Tuesday, April 29th. The company reported $1.24 EPS for the quarter, topping analysts’ consensus estimates of $1.10 by $0.14. AstraZeneca had a return on equity of 33.14% and a net margin of 14.14%. The business had revenue of $13.59 billion during the quarter, compared to the consensus estimate of $13.71 billion. During the same period in the previous year, the company posted $2.06 earnings per share. The business’s revenue for the quarter was up 7.2% on a year-over-year basis. On average, equities research analysts forecast that AstraZeneca PLC will post 4.51 EPS for the current fiscal year.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.